Method of treating a person afflicted with a respiratory condition and pharmaceutical formulation including dapsone
Inventors
Sekhavat, Houfar • Asotra, Satish
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-12396967-B2
Publication Date
2025-08-26
Expiration Date
Abstract
A method for treating patients with COVID-19 and/or other respiratory conditions includes administering eighty-five milligrams of dapsone twice daily for twenty-one days. A variety of dapsone formulations and delivery devices are disclosed, including an inhaler, nasal spray, nasal gel, otic formulation, intravenous formulation, oral solution, oral suspension, patch and suppository.
Core Innovation
The invention relates to treating acute respiratory distress syndrome by administering dapsone to a person afflicted with acute respiratory distress syndrome. The dosage of dapsone comprises 75-100 milligrams of dapsone twice per day.
The invention further provides treatment of inflammatory respiratory conditions by administering dapsone in defined dosages and regimens, including twice per day administration for specified durations. Specific dosage examples include 80-90 milligrams of dapsone twice per day and 85 milligrams of dapsone twice per day, with administration periods described as ten to fourteen days, ten days, or twenty-one days.
The invention additionally relates to treating rhinitis and sinusitis by administering a nasal spray into a person's nasal cavity. The nasal spray comprises a dosage of dapsone in a liquid solution, wherein the dosage comprises 75-100 milligrams of dapsone, and the nasal spray further comprises at least one antibiotic selected from the group consisting of azithromycin and doxycycline.
The nasal spray liquid solution is described as an aqueous solution and may include glycerin and at least one co-emulsifier selected from lauroyl polyoxyl-6 glycerides and oleoyl polyoxyl-6 glycerides.
Claims Coverage
The provided claim coverage includes three independent claims covering acute respiratory distress syndrome, rhinitis, and sinusitis treatment. The main inventive features are the defined dapsone dose ranges, twice-per-day administration, and the nasal spray liquid-solution configuration with an antibiotic selected from azithromycin and doxycycline.
Twice-daily dapsone dosing for acute respiratory distress syndrome
A method of treating a person afflicted with acute respiratory distress syndrome comprising administering to the person a dosage of dapsone comprising 75-100 milligrams of dapsone twice per day.
Antibiotic-combined dapsone nasal spray for rhinitis
A method of treating a person afflicted with rhinitis comprising administering a nasal spray into the person's nasal cavity, the nasal spray comprising a dosage of dapsone in a liquid solution, wherein the dosage of dapsone comprises 75-100 milligrams of dapsone and wherein the nasal spray further comprises at least one antibiotic selected from the group consisting of azithromycin and doxycycline.
Antibiotic-combined dapsone nasal spray for sinusitis
A method of treating a person afflicted with sinusitis comprising administering a nasal spray into the person's nasal cavity, the nasal spray comprising a dosage of dapsone in a liquid solution, wherein the dosage of dapsone comprises 75-100 milligrams of dapsone and wherein the nasal spray further comprises at least one antibiotic selected from the group consisting of azithromycin and doxycycline.
Overall, the independent claims center on administering dapsone at 75-100 milligrams twice per day for acute respiratory distress syndrome, and administering a nasal spray into the nasal cavity for rhinitis and sinusitis where the nasal spray contains a dapsone liquid solution and an antibiotic selected from azithromycin and doxycycline.
Stated Advantages
Not explicitly described in patent.
Documented Applications
Treating acute respiratory distress syndrome by administering dapsone dosed at 75-100 milligrams twice per day.
Treating rhinitis by administering a dapsone-containing nasal spray liquid solution (75-100 milligrams) together with at least one antibiotic selected from azithromycin and doxycycline.
Treating sinusitis by administering a dapsone-containing nasal spray liquid solution (75-100 milligrams) together with at least one antibiotic selected from azithromycin and doxycycline.
Interested in licensing this patent?